YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Biogen Inc. (BIIB), which belongs to the Zacks Medical - Biomedical and Genetics…
[Lupus, Systemic Lupus Erythematosus. autoimmune disease. Immune system disorders. Medical stethoscope and word written on wooden blocks, pastel blue background, copy space] Andrzej Rostek/iStock via Getty Images * Long-term phase 2 data f…
[Wall Street] hapabapa * Wells Fargo started Design Therapeutics (DSGN [https://seekingalpha.com/symbol/DSGN]) off at overweight as it sees its Friedreich ataxia candidate, DT-216P2, as having "potentially best-in-disease functional improv…
Biogen Inc. Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease acti…
AbbVie ABBV continues to expand its neuroscience franchise. The company recently secured FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease (PD). A commercial launch is targeted for October 2026. Juvmo Expands AbbV…
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:H…
1 Profitable Stock Worth Investigating and 2 We Ignore Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn't mean it will thrive tom…
TORONTO, Oct. 1, 2026 /CNW/ -- HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. Th…
Biogen BIIB has been undergoing a major transformation. The company has long been seeing declining sales of its key multiple sclerosis ("MS") due to generic competition for Tecfidera globally, biosimilar competition for Tysabri in Europe a…
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) an…
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q2. Today, we are lookin…
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer's disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improv…
Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets ©@Totojang from Getty Images via Canva, @Artsanova from Getty Images via Canva Key Stats for Novo Nordisk Stock Price change for Novo Nordisk stock in last 1 year:…
With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to rec…
Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen's rec…
Reflecting On Therapeutics Stocks' Q2 Earnings: AbbVie (NYSE:ABBV) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at AbbVie (NYSE:ABBV) and its peers. Over the n…
Alzheimer's Disease International ("ADI") observes Sept. 21 as World Alzheimer's Day, while September is marked as World Alzheimer's Month to raise awareness about Alzheimer's disease (AD) and other forms of dementia. The 2026 campaign — T…
Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aim…
Biogen Inc. EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT study Publicati…
AbbVie ABBV has significantly transformed its neuroscience portfolio over the years, evolving it from a relatively concentrated business initially anchored by Vraylar and Botox Therapeutics into a broader, multi-franchise platform. The com…
Biogen logo is seen at its headquarters in Cambridge, Massachusetts By Tada Images Biogen Inc. (BIIB) is a global biotechnology company that develops and commercializes therapies for serious and complex diseases. Headquartered in Cambridge…
Biogen Inc. The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive Disease TOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc.…
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)'s ratings from Peer Perform, with Wolfe assigning them similar $300 pri…
Hummingbird Bioscience Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience…
Key Points Interested in Biogen Inc.? Here are five stocks we like better. Biogen's pipeline is reaching a pivotal stage: The company now has 10 Phase III programs, with clinical readouts beginning in the fourth quarter, as it seeks to off…
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:V…
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Over t…
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's next…
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN) Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next fe…
HMG Strategy FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encou…
Eli Lilly and Company LLY boasts a wide range of products across cardiometabolic health, neuroscience, oncology and immunology. Cardiometabolic Health is Lilly's largest therapeutic area by a wide margin, particularly with the success of i…
Businessman trading stock market on teblet screen by Nespix via iStock Software earnings have been strong lately, and Veeva Systems (VEEV) stood out with one of the market's biggest post-earnings moves. Shares of the life sciences cloud so…
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere. Continue Reading
A month has gone by since the last earnings report for Exelixis (EXEL). Shares have added about 13.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Exe…
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves…
Biogen Inc. –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of sta…